Third Harmonic Bio Inc. (THRD) - Total Assets
Based on the latest financial reports, Third Harmonic Bio Inc. (THRD) holds total assets worth $279.84 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Third Harmonic Bio Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Third Harmonic Bio Inc.'s total assets have evolved over time, based on quarterly financial data. Also see Third Harmonic Bio Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Third Harmonic Bio Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Third Harmonic Bio Inc.'s total assets of $279.84 Million consist of 98.6% current assets and 1.4% non-current assets. Review Third Harmonic Bio Inc. total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Third Harmonic Bio Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Third Harmonic Bio Inc. stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Third Harmonic Bio Inc.'s current assets represent 98.6% of total assets in 2024, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 96.8% of total assets in 2024, down from 98.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Third Harmonic Bio Inc. Competitors by Total Assets
Key competitors of Third Harmonic Bio Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Third Harmonic Bio Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 54.10 | 66.10 | 22.72 |
| Quick Ratio | 54.10 | 66.10 | 22.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $270.89 Million | $261.58 Million | $123.48 Million |
Third Harmonic Bio Inc. - Advanced Valuation Insights
This section examines the relationship between Third Harmonic Bio Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.89 |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | 6.1% |
| Total Assets | $294.61 Million |
| Market Capitalization | $242.79 Million USD |
Valuation Analysis
Near Book Valuation: The market values Third Harmonic Bio Inc.'s assets close to their book value (0.82x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Third Harmonic Bio Inc.'s assets grew by 6.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Third Harmonic Bio Inc. (2020–2024)
The table below shows the annual total assets of Third Harmonic Bio Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $294.61 Million | +6.08% |
| 2023-12-31 | $277.71 Million | -7.02% |
| 2022-12-31 | $298.68 Million | +131.24% |
| 2021-12-31 | $129.16 Million | +1431.65% |
| 2020-12-31 | $8.43 Million | -- |
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more